Insider Transactions Reported by 19 Insiders of Opus Genetics, Inc.

Symbol: IRD on Nasdaq
Location: Durham, NC

Quick Takeaways

IRD - Opus Genetics, Inc. has 19 insiders with reported activity on this page.
Net insider value flow over the last year: -$8,658,616.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $323,693; sell value: $8,982,309.
Net share flow: -3,909,395.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$8,658,616.

Buys

$323,693

Shares: 164,000

Insiders: 1

Sells

$8,982,309

Shares: 4,073,395

Insiders: 7

Net

-$8,658,616

Shares: -3,909,395

Insiders: -6

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	73,395	$0	$382,309	-$382,309
3-6	164,000	4,000,000	$323,693	$8,600,000	-$8,276,307
6-9	0	0	$0	$0	$0
9-12	0	0	$0	$0	$0

Opus Genetics, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Foundation Fighting Blindness Retinal Degeneration Fund	Director, Other*	$11,808,167	-$8,600,000	-42%	Filing P/S	09 Dec 2025
Cam Gallagher	Director	$9,549,526	+$323,693	+3.5%	Median	20 Apr 2026
George Magrath	Chief Executive Officer, Director	$9,089,815	-$176,974	-1.9%	Filing P/S	23 Apr 2026
Benjamin R. Yerxa	President, Director	$3,726,379	-$39,121	-1%	Filing P/S	23 Apr 2026
Robert E. Gagnon	Chief Financial Officer	$3,070,102	-$40,658	-1.3%	Filing P/S	23 Apr 2026
Ashwath Jayagopal	Chief Scientific & Dev. Ofc.	$2,643,784	-$58,202	-2.2%	Filing P/S	23 Apr 2026
Richard J. Rodgers	Director	$1,560,750			Median	20 Apr 2026
Joseph K. Schachle	Chief Operating Officer	$1,545,617	-$44,044	-2.8%	Filing P/S	23 Apr 2026
Sean Ainsworth	Director	$1,463,698			Median	20 Apr 2026
James S. J. Manuso	Director	$1,443,796			Median	20 Apr 2026
Jean Bennett	Director	$1,178,536			Median	20 Apr 2026
Susan Benton	Director	$1,109,717			Median	20 Apr 2026
Rabourn Amy Zaremba	Head of Fin. Quality Assurance	$981,843	-$23,310	-2.3%	Filing P/S	23 Apr 2026
Adrienne L. Graves	Director	$580,188			Median	20 Apr 2026
Jay Pepose	Director	$318,508			Mixed	11 Jun 2024
Ronil A. Patel	Chief Business Officer	$296,181			Mixed	10 Jan 2024
Nirav S. Jhaveri	Chief Financial Officer	$223,437			Mixed	13 Mar 2025
Bernhard Hoffmann	SVP of Corp. Dev.	$213,263			Mixed	13 Mar 2025
Mina Sooch	President and CEO, Director	$163,250			Mixed	10 Jan 2023

Top shareholders of Opus Genetics, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
PERCEPTIVE ADVISORS LLC	13D/G 13F	Company	10%	7,174,154	$14,420,050	+$5,353,943	31 Dec 2025	13D/G 13F
Nantahala Capital Management, LLC	13D/G 13F	Company	10%	7,123,506	$14,318,247	+$1,755,146	31 Dec 2025	13D/G 13F
Foundation Fighting Blindness Retinal Degeneration Fund	3/4/5 13D/G	Director, Other*	8% from 13D/G	5,492,171	$11,808,167	-$8,600,000	09 Dec 2025	3/4/5 13D/G
BALYASNY ASSET MANAGEMENT L.P.	13D/G 13F	Company	7.4%	5,110,373	$10,271,850	$0	31 Dec 2025	13D/G 13F
Cam Gallagher	3/4/5	Director	— mixed-class rows	2,962,703 mixed-class rows	$9,549,526	+$323,693	20 Apr 2026	3/4/5
BIOS Capital Management, LP	13F	Company	— mixed-class rows	5,374,180 mixed-class rows	$9,364,963	—	31 Dec 2025	13F
George Magrath	3/4/5	Chief Executive Officer, Director	— mixed-class rows	2,133,501 mixed-class rows	$9,089,815	-$176,974	23 Apr 2026	3/4/5
VANGUARD GROUP INC	13F	Company	— mixed-class rows	3,488,704 mixed-class rows	$6,021,358	—	31 Dec 2025	13F
Voss Capital, LP	13F	Company	— mixed-class rows	4,685,860 mixed-class rows	$5,811,205	—	31 Dec 2025	13F
BIOS Fund III, LP	13D/G	BIOS EQUITY PARTNERS III, LP	6.2%	3,683,429	$5,156,801	$0	05 May 2025	13D/G
MILLENNIUM MANAGEMENT LLC	13F	Company	2.8%	2,002,550	$4,025,125	—	31 Dec 2025	13F
Benjamin R. Yerxa	3/4/5	President, Director	0.99%	711,535	$3,726,379	-$39,121	23 Apr 2026	3/4/5
Mink Brook Asset Management LLC	13F	Company	2.3%	1,665,631	$3,347,918	—	31 Dec 2025	13F
Robert E. Gagnon	3/4/5	Chief Financial Officer	— mixed-class rows	842,158 mixed-class rows	$3,070,102	-$40,658	23 Apr 2026	3/4/5
Ashwath Jayagopal	3/4/5	Chief Scientific & Dev. Ofc.	0.71%	509,233	$2,643,784	-$58,202	23 Apr 2026	3/4/5
Opaleye Management Inc.	13F	Company	1.6%	1,120,000	$2,251,200	—	31 Dec 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	1.5%	1,104,996	$2,221,042	—	31 Dec 2025	13F
Richard J. Rodgers	3/4/5	Director	— mixed-class rows	422,614 mixed-class rows	$1,560,750	—	20 Apr 2026	3/4/5
Joseph K. Schachle	3/4/5	Chief Operating Officer	0.41%	296,084	$1,545,617	-$44,044	23 Apr 2026	3/4/5
Bleichroeder LP	13F	Company	1%	736,842	$1,481,052	—	31 Dec 2025	13F
Sean Ainsworth	3/4/5	Director	— mixed-class rows	401,284 mixed-class rows	$1,463,698	—	20 Apr 2026	3/4/5
James S. J. Manuso	3/4/5	Director	— mixed-class rows	396,910 mixed-class rows	$1,443,796	—	20 Apr 2026	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	— mixed-class rows	789,538 mixed-class rows	$1,345,885	—	31 Dec 2025	13F
Jean Bennett	3/4/5	Director	— mixed-class rows	338,611 mixed-class rows	$1,178,536	—	20 Apr 2026	3/4/5
Susan Benton	3/4/5	Director	— mixed-class rows	323,486 mixed-class rows	$1,109,717	—	20 Apr 2026	3/4/5
Rabourn Amy Zaremba	3/4/5	Head of Fin. Quality Assurance	0.26%	188,671	$981,843	-$23,310	23 Apr 2026	3/4/5
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO	13F	Company	1.9%	511,610	$593,468	—	31 Dec 2025	13F
Adrienne L. Graves	3/4/5	Director	— mixed-class rows	207,106 mixed-class rows	$580,188	—	20 Apr 2026	3/4/5
Prosight Management, LP	13F	Company	1.7%	442,600	$513,416	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	— mixed-class rows	300,804 mixed-class rows	$502,546	—	31 Dec 2025	13F
Cable Car Capital, LP	13F	Company	1.6%	420,000	$487,200	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.34%	241,871	$486,161	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	— mixed-class rows	260,630 mixed-class rows	$473,720	—	31 Dec 2025	13F
Texas Capital Bank Wealth Management Services Inc	13F	Company	— mixed-class rows	340,125 mixed-class rows	$460,845	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	— mixed-class rows	249,157 mixed-class rows	$436,288	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	— mixed-class rows	193,021 mixed-class rows	$352,519	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	— mixed-class rows	196,903 mixed-class rows	$349,020	—	31 Dec 2025	13F
Jay Pepose	3/4/5	Director	— mixed-class rows	215,639 mixed-class rows	$318,508	—	11 Jun 2024	3/4/5
MARSHALL WACE, LLP	13F	Company	0.22%	157,648	$316,873	—	31 Dec 2025	13F
Sigma Planning Corp	13F	Company	0.94%	247,277	$298,615	—	31 Dec 2025	13F
Ronil A. Patel	3/4/5	Chief Business Officer	— mixed-class rows	165,252 mixed-class rows	$296,181	—	10 Jan 2024	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	— mixed-class rows	149,009 mixed-class rows	$280,213	—	31 Dec 2025	13F
GAGNON SECURITIES LLC	13F	Company	0.91%	240,220	$278,655	—	31 Dec 2025	13F
Senvest Management, LLC	13F	Company	0.88%	230,895	$267,838	—	31 Dec 2025	13F
Creative Planning	13F	Company	0.18%	128,366	$258,016	—	31 Dec 2025	13F
Nirav S. Jhaveri	3/4/5	Chief Financial Officer	— mixed-class rows	246,793 mixed-class rows	$223,437	—	13 Mar 2025	3/4/5
NORTHERN TRUST CORP	13F	Company	— mixed-class rows	127,916 mixed-class rows	$222,712	—	31 Dec 2025	13F
Bernhard Hoffmann	3/4/5	SVP of Corp. Dev.	— mixed-class rows	214,946 mixed-class rows	$213,263	—	13 Mar 2025	3/4/5
UBS Group AG	13F	Company	— mixed-class rows	99,334 mixed-class rows	$191,573	—	31 Dec 2025	13F
OMERS ADMINISTRATION Corp	13F	Company	0.12%	87,900	$176,679	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Opus Genetics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Benjamin R. Yerxa	IRD	Common Stock	Sale	-1.04%	$39,121	$5.24	-7,470	711,535	23 Apr 2026	Direct
Joseph K. Schachle	IRD	Common Stock	Sale	-1.56%	$24,519	$5.22	-4,697	296,084	23 Apr 2026	Direct
Rabourn Amy Zaremba	IRD	Common Stock	Sale	-0.86%	$8,540	$5.20	-1,641	188,671	23 Apr 2026	Direct
George Magrath	IRD	Common Stock	Sale	-0.54%	$49,647	$5.22	-9,511	1,741,344	23 Apr 2026	Direct
Ashwath Jayagopal	IRD	Common Stock	Sale	-1.46%	$39,156	$5.19	-7,542	509,233	23 Apr 2026	Direct
Robert E. Gagnon	IRD	Common Stock	Sale	-1.31%	$40,658	$5.18	-7,842	592,158	23 Apr 2026	Direct
Richard J. Rodgers	IRD	Common Stock	Award	7.65%			24,367	343,022	20 Apr 2026	Direct
James S. J. Manuso	IRD	Common Stock	Award	8.32%			24,367	317,318	20 Apr 2026	Direct
Adrienne L. Graves	IRD	Common Stock	Award	23.6%			24,367	127,514	20 Apr 2026	Direct
Cam Gallagher	IRD	Common Stock	Award	1.22%			24,367	2,015,797	20 Apr 2026	Direct
Susan Benton	IRD	Common Stock	Award	11.1%			24,367	243,894	20 Apr 2026	Direct
Jean Bennett	IRD	Common Stock	Award	10.4%			24,367	259,019	20 Apr 2026	Direct
Sean Ainsworth	IRD	Common Stock	Award	8.2%			24,367	321,692	20 Apr 2026	Direct
Joseph K. Schachle	IRD	Common Stock	Sale	-1.22%	$19,525	$5.25	-3,719	300,781	16 Mar 2026	Direct
Rabourn Amy Zaremba	IRD	Common Stock	Sale	-1.46%	$14,770	$5.24	-2,816	190,312	16 Mar 2026	Direct
George Magrath	IRD	Common Stock	Sale	-1.38%	$127,327	$5.21	-24,438	1,750,855	16 Mar 2026	Direct
Ashwath Jayagopal	IRD	Common Stock	Sale	-0.71%	$19,046	$5.12	-3,719	516,775	16 Mar 2026	Direct
Ashwath Jayagopal	IRD	Common Stock	Tax liability	-1.01%			-5,313	520,494	12 Feb 2026	Direct
Rabourn Amy Zaremba	IRD	Common Stock	Award	81.1%			86,500	193,128	22 Jan 2026	Direct
George Magrath	IRD	Common Stock	Award	37.4%			483,639	1,775,293	22 Jan 2026	Direct
Ashwath Jayagopal	IRD	Common Stock	Award	318%			400,000	525,807	22 Jan 2026	Direct
Robert E. Gagnon	IRD	Common Stock	Award	200%			400,000	600,000	22 Jan 2026	Direct
Joseph K. Schachle	IRD	Common Stock	Award	458.7%			250,000	304,500	22 Jan 2026	Direct
Benjamin R. Yerxa	IRD	Common Stock	Award	125.4%			400,000	719,005	22 Jan 2026	Direct
Rabourn Amy Zaremba	IRD	Common Stock	Tax liability	-3.08%			-3,390	106,628	18 Jan 2026	Direct
Rabourn Amy Zaremba	IRD	Common Stock	Tax liability	-3.47%			-3,950	110,018	10 Jan 2026	Direct
Cam Gallagher	IRD	Common Stock	Award	3.48%			67,000	1,991,430	06 Jan 2026	Direct
James S. J. Manuso	IRD	Common Stock	Award	11.9%			31,188	292,951	01 Jan 2026	Direct
Adrienne L. Graves	IRD	Common Stock	Award	29.7%			23,643	103,147	01 Jan 2026	Direct
Jean Bennett	IRD	Common Stock	Award	9.89%			21,127	234,652	01 Jan 2026	Direct
Sean Ainsworth	IRD	Common Stock	Award	16.7%			42,507	297,325	01 Jan 2026	Direct
Cam Gallagher	IRD	Common Stock	Award	1.74%			33,000	1,924,430	31 Dec 2025	Direct
Cam Gallagher	IRD	Common Stock	Purchase		$163,419	$1.97	83,000	83,000	29 Dec 2025	By Garret Gallagher - Custodian UTMA/UGMA
Cam Gallagher	IRD	Common Stock	Purchase	4.47%	$160,275	$1.98	81,000	1,891,430	29 Dec 2025	Direct
Foundation Fighting Blindness Retinal Degeneration Fund	IRD	Common Stock	Sale	-42.1%	$8,600,000	$2.15	-4,000,000	5,492,171	09 Dec 2025	Direct
George Magrath	IRD	Common Stock	Tax liability	-2.3%			-30,350	1,291,654	01 Nov 2025	Direct
Benjamin R. Yerxa	IRD	Common Stock	Tax liability	-6.94%			-23,795	319,005	22 Oct 2025	Direct
Robert E. Gagnon	IRD	Common Stock	Award				200,000	200,000	10 Sep 2025	Direct
Robert E. Gagnon	IRD	Employee Stock Option (right to buy)	Award				250,000	250,000	02 Sep 2025	Direct
Cam Gallagher	IRD	Common Stock	Award	92.4%			869,565	1,810,430	25 Aug 2025	Direct
Sean Ainsworth	IRD	Common Stock	Award	51.8%			86,956	254,818	25 Aug 2025	Direct
Foundation Fighting Blindness Retinal Degeneration Fund	IRD	Common Stock	Conversion of derivative security	270.1%			6,927,419	9,492,171	05 May 2025	Direct
Foundation Fighting Blindness Retinal Degeneration Fund	IRD	Series A Non-Voting Convertible Preferred Stock	Conversion of derivative security	-100%			-6,927	0	05 May 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.